Lantern Pharma posts LP-300 Phase 2 trial presentation

Lantern Pharma Inc. furnished an investor-style presentation used on June 1, 2026 to support discussions about the Harmonic™ Phase 2 clinical trial for its LP-300 product candidate.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lantern Pharma Inc. furnished an investor-style presentation used on June 1, 2026 to support discussions about the Harmonic™ Phase 2 clinical trial for its LP-300 product candidate. The presentation is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.

The company notes that the material provided under this disclosure is considered "furnished," not "filed," which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Regulation FD Disclosure, Phase 2 clinical trial, product candidate, furnished as Exhibit 99.1, +1 more

5 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure."

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Phase 2 clinical trial medical

"regarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300."

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

product candidate medical

"for the Company’s product candidate known as LP-300."

furnished as Exhibit 99.1 regulatory

"A copy of the presentation is furnished as Exhibit 99.1"

Inline XBRL technical

"Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)."

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lantern Pharma (LTRN) disclose in this 8-K filing?

Lantern Pharma furnished a presentation used on June 1, 2026 discussing the Harmonic™ Phase 2 clinical trial of LP-300. The slide deck is attached as Exhibit 99.1 for investors and stakeholders to review the program’s status and discussion materials.

What is Exhibit 99.1 in Lantern Pharma’s (LTRN) June 2026 8-K?

Exhibit 99.1 is a presentation relating to June 1, 2026 discussions about the Harmonic™ LP-300 Phase 2 clinical trial. It contains the materials Lantern Pharma used to assist its discussions regarding this clinical study and associated information.

How is the LP-300 Harmonic™ Phase 2 trial described in the Lantern Pharma (LTRN) 8-K?

The LP-300 Harmonic™ Phase 2 trial is identified as the focus of a June 1, 2026 presentation. Lantern Pharma used the presentation to assist discussions about this clinical trial for its LP-300 product candidate and furnished it as Exhibit 99.1.

Is the Lantern Pharma (LTRN) LP-300 presentation considered filed with the SEC?

No, the LP-300 presentation is treated as information that is "furnished," not "filed," under the Exchange Act. Lantern Pharma states it is not subject to Section 18 liabilities and is not incorporated into other filings unless specifically referenced.

Does the Lantern Pharma (LTRN) 8-K include financial statements or earnings data?

The 8-K identifies Item 7.01 Regulation FD Disclosure and Item 9.01 for exhibits, but the described content centers on a presentation about the Harmonic™ LP-300 Phase 2 clinical trial rather than financial statements or earnings metrics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/01/2026 - 07:40 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2026

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1920 McKinney Avenue, 7th Floor

Dallas, Texas

75201

(Address of Principal Executive Offices)

(Zip Code)

(972) 277-1136

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		LTRN		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 1, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s discussions regarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300.

A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit Description

99.1		Presentation relating to June 1, 2026 discussions regarding the Harmonic™ LP-300 Phase 2 clinical trial.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.